Sugi Predict

Sugi Predict / Compounds / SCHEMBL551121

SCHEMBL551121

SCHEMBL551121

CCCCCCCCc1ccccc1I

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ LIPG Q9Y5X9 1/20 0.58
▸ TAAR1 Q96RJ0 1/20 0.52
▸ NR1H2 P55055 1/20 0.47
▸ NR1H3 Q13133 1/20 0.47
▸ BID P55957 3/20 0.45
▸ MCL1 Q07820 3/20 0.45
▸ BCL2L1 Q07817 2/20 0.45
▸ BAK1 Q16611 2/20 0.45
▸ KAT8 Q9H7Z6 2/20 0.45
▸ MAPT P10636 1/20 0.45
▸ PPARG P37231 1/20 0.45
▸ PPARA Q07869 1/20 0.45
▸ EP300 Q09472 1/20 0.45
▸ KAT2A Q92830 1/20 0.45
▸ KAT2B Q92831 1/20 0.45
▸ KAT5 Q92993 1/20 0.45
▸ SAE1 Q9UBE0 1/20 0.45
▸ THRA P10827 1/20 0.44
▸ THRB P10828 1/20 0.44
▸ KCNH2 Q12809 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3899345 1.00 LIPG (0.58) LIPGTAAR1NR1H2NR1H3BID
SCHEMBL29554553 1.00 LIPG (0.58) LIPGTAAR1NR1H2NR1H3BID
SCHEMBL8766368 1.00 LIPG (0.58) LIPGTAAR1NR1H2NR1H3BID
SCHEMBL5599179 1.00 LIPG (0.58) LIPGTAAR1NR1H2NR1H3BID
SCHEMBL14302122 0.98 LIPG (0.55) LIPGTAAR1NR1H2NR1H3BID
SCHEMBL21295285 0.93 LIPG (0.51) LIPGTAAR1NR1H2NR1H3BID
SCHEMBL27817584 0.93 LIPG (0.51) LIPGTAAR1NR1H2NR1H3BID
SCHEMBL4181180 0.91 TAAR1 (0.56) LIPGTAAR1NR1H2NR1H3BID
SCHEMBL6275064 0.91 KCNH2 (0.54) LIPGTAAR1KAT8EP300KAT5
Sulfuric Acid SCHEMBL10771006 0.89 LIPG (0.53) LIPGTAAR1NR1H2NR1H3BID

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-106397224-A A novel synthetic method of fingolimod 东莞明日医药有限公司 2017-02-15 — — CN claimed
US-20250019341-A1 COMPOUNDS AND METHOD OF USE THEREOF FOR TREATING BACTERIAL DISEASES INSTITUTE OF GENETICS AND DEVELOPMENTAL BIOLOGY, CHINESE ACADEMY OF SCIENCES (CN) 2025-01-16 — — US disclosed
EP-4444694-A1 COMPOUNDS AND METHOD OF USE THEREOF FOR TREATING BACTERIAL DISEASES Peking University (CN) 2024-10-16 — — EP disclosed
CN-118510752-A Compounds for the treatment of bacterial diseases and methods of use thereof 北京大学 2024-08-16 — — CN disclosed
WO-2023104017-A1 COMPOUNDS AND METHOD OF USE THEREOF FOR TREATING BACTERIAL DISEASES PEKING UNIVERSITY (CN) 2023-06-15 — — WO disclosed
WO-2023104017-A1 COMPOUNDS AND METHOD OF USE THEREOF FOR TREATING BACTERIAL DISEASES PEKING UNIVERSITY (CN) 2023-06-15 — — WO disclosed
US-20140088313-A1 SUBSTITUTED INDOLOCARBAZOLES XEROX CORPORATION (US) 2014-03-27 — — US disclosed
US-8609867-B2 Substituted indolocarbazoles XEROX CORPORATION (US) 2013-12-17 — — US disclosed
US-20120157689-A1 SUBSTITUTED INDOLOCARBAZOLES XEROX CORPORATION (US) 2012-06-21 — — US disclosed
US-8110690-B2 Substituted indolocarbazoles XEROX CORPORATION (US) 2012-02-07 — — US disclosed
US-7851074-B2 Organic electroluminescent display device and chemical compounds for liquid crystals TOHOKU PIONEER CORPORATION (JP) 2010-12-14 — — US disclosed
US-20090058277-A1 Organic Electroluminescent Display Device and Chemical Compounds for Liquid Crystals TOHOKU PIONEER CORPORATION (JP) 2009-03-05 — — US disclosed
US-20090036689-A1 SUBSTITUTED INDOLOCARBAZOLES XEROX CORPORATION (US) 2009-02-05 — — US disclosed
US-7456424-B2 Thin film transistors including indolocarbozoles XEROX CORPORATION (US) 2008-11-25 — — US disclosed
US-20070164257-A1 Organic electroluminescent display device and chemical compounds for liquid crystals TOHOKU PIONEER CORPORATION 2007-07-19 — — US disclosed
US-7195826-B2 Charge transfer compounds; containing organiridium compound TOHOKU PIONEER CORPORATION (JP) 2007-03-27 — — US disclosed
US-20060124923-A1 Thin film transistors including indolocarbazoles XEROX CORPORATION 2006-06-15 — — US disclosed
US-20060125009-A1 Thin film transistors including indolocarbazoles XEROX CORPORATION 2006-06-15 — — US disclosed
US-20040043252-A1 Organic electroluminescent display device and chemical compounds for liquid crystals KIDO JUNJI (JP) 2004-03-04 — — US disclosed
US-20010048982-A1 Organic electroluminescent display device and chemical compounds for liquid crystals TOHOKU PIONEER CORPORATION 2001-12-06 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090036689-A1 SUBSTITUTED INDOLOCARBAZOLES HTR3C, HTR3A, AANAT LIPG 4503/4885TAAR1 1645/4885NR1H2 2881/4885
US-20250019341-A1 COMPOUNDS AND METHOD OF USE THEREOF FOR TREATING BACTERIAL DISEASES TLR3, CGAS, NOD2 LIPG 1322/4885TAAR1 3334/4885NR1H2 2364/4885
US-20120157689-A1 SUBSTITUTED INDOLOCARBAZOLES HTR3C, HTR3A, AANAT LIPG 4503/4885TAAR1 1645/4885NR1H2 2881/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.